Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.

ABSTRACT:

Purpose

Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion status, no genomic markers are available for risk stratification. We present an international consortium study designed to determine the incidence of driver mutations and their association with clinical outcome.

Patients and methods

Tumor samples collected from patients enrolled on Children's Oncology Group trials (1998-2017) and UK patients enrolled on malignant mesenchymal tumor and RMS2005 (1995-2016) trials were subjected to custom-capture sequencing. Mutations, indels, gene deletions, and amplifications were identified, and survival analysis wa

SUBMITTER: Shern JF 

PROVIDER: S-EPMC8425837 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature